LIVE · 31 SOURCES
Search stories, MPs, sources
News
Latest news Full archive Activity log Weather Blindspot Divergence Clusters
Politics
Political parties MPs, Senate & ridings Municipal Lobbying Appointments Ethics tracker Officers
Elections
Election calendar Candidates & races Ridings directory Candidate search Party records Federal Provincial Municipal Coverage readiness Ridings
Money
Economy Bank of Canada rates Cost of Parliament Global Affairs spending Debt tracker Where the money goes Markets
Media
Sources Owners Journalists CRTC Echo — slogans & phrases
Data
Coverage map Accountability chain Cross-Watch Claims Developer API Education API Search everything
About
Methodology The newsroom Governance & ethics C.R.E.E.D. Media literacy Score an article Subscribe to What The Fact Sign in →
← Back to News  ·  1 outlet · Story cluster #604

With Canada approving 1st generic semaglutide, how will costs compare?

How different outlets framed the same story — bias, verdict, and framing side by side.
🤖 D.R.A.F.T. Summary
Manufactured by Dr. Reddy’s Laboratories in India, the injectable medication has been approved for once-a-week treatment of Type 2 diabetes in adults.
Outlets covering this story
Global News CENTER
Only one perspective covered this story — no diversity detected
📰
Side-by-Side Outlet Comparison — Starter+
See how 1 outlets framed this story — bias by source, F.A.C.T. framing analysis, and verdict side by side.
Unlock with Starter →